RBC Capital Raises Price Target on Moderna (MRNA) Amid Sector Momentum

On July 7, 2026, RBC Capital raised its price target for Moderna Inc. (NASDAQ:MRNA) to $45 from $38 while maintaining a 'Sector Perform' rating. The firm cited strong momentum in the biotech sector driven by positive data and improved FDA perceptions ahead of Q2 earnings.

By Jeff Lewis Thu, July 9, 2026 at 1:41 PM GMT+3 2 min read · Yahoo Finance · July 9, 2026, 10:41 UTC

RBC Capital Raises Price Target on Moderna (MRNA) Amid Sector Momentum

Tickers: $MRNA

Topics: Biotech Earnings Preview M&A Activity

Read the full article at Yahoo Finance

More World news

Parsons Reports Strong Third Quarter Results Driven by High-Margin Product Shift Motley Fool · November 12, 2026, 18:45 UTC
C.H. Robinson Reports Q3 2026 Earnings Driven by AI Efficiency and Margin Expansion Motley Fool · November 12, 2026, 18:45 UTC
Baker Hughes Raises Guidance Amid Surging Data Center Power Demand Motley Fool · November 12, 2026, 18:45 UTC
California Supreme Court to Rule on Insurance Overcharge Liability Under Proposition 103 PR Newswire · November 12, 2026, 18:44 UTC
Federal Court Orders Veterans Guardian to Pay Treble Damages to Disabled Veteran Class PR Newswire · November 12, 2026, 18:41 UTC
AIRO Group Holdings Reaffirms 2026 Revenue Growth Guidance Amid $200 Million Drone Backlog Seeking Alpha · November 12, 2026, 18:40 UTC
Nvidia CEO Jensen Huang Resigns Amid Personal Scandal, Raising Uncertainty for Open Source AI Strategy TechCrunch · November 12, 2026, 18:39 UTC
Vor Bio and RemeGen Expand Collaboration for Autoimmune Disease Therapy Seeking Alpha · November 12, 2026, 18:35 UTC
EnterpriseDB Hires CMRD Engineering Team to Strengthen Sovereign AI Governance PR Newswire · November 12, 2026, 18:36 UTC
Alliant Credit Union Executive Meredith Ritchie Named 2027 Chicago Titan 100 Honoree PR Newswire · November 12, 2026, 18:36 UTC